Gilead Sciences Inc (GIS)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 138.94 |
|---|---|
| 52-week range | 98.96 – 142.80 |
| Return, 1 month / 3 months | +4.5% / +21.3% |
| Return, 1 year / 3 years | +34.8% / +104.8% |
| Trend | Uptrend |
| RSI (14) | 60 |
| Volatility (1 year) | 24.8% |
| Worst drawdown (1 year) | -18.6% |
| Average daily value traded | 0.12M EUR |
| Dividend yield | 1.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Gilead Sciences is a biopharmaceutical company based in California that researches, develops and sells medicines, chiefly for viral infections. Its products include treatments for HIV and hepatitis C, along with therapies for other serious conditions such as certain cancers and inflammatory diseases. The company serves patients and healthcare providers through hospitals, clinics and pharmacies, working with health systems and governments around the world to make its medicines available.
The shares are listed on the XETRA Stock Exchange in Germany under the code GIS, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Gilead Sciences Inc (GIS) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 138.94 on 22 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 41 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 34.8% and over the last three months it rose 21.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 16.9% | ||
| From 52-week high | -2.2% | ||
| Momentum | 85 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 21.3% | ||
| 6-month return | 24.8% | ||
| 12-month return, skipping the last month | 29.0% | ||
| Stability (higher is calmer) | 82 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.6% | ||
| Liquidity | 47 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.12M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 63 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.9% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −2.2% |
|---|---|
| 1 month | +4.5% |
| 3 months | +21.3% |
| 6 months | +24.8% |
| 1 year | +34.8% |
| 3 years | +104.8% |
| 5 years | +187.3% |
Signals
| 50-day / 200-day average | 129.54 / 118.89 |
|---|---|
| Golden / death cross (60 days) | Golden, 51 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.05 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Sep 2026 | USD 0.7294 |
| 15 Jun 2026 | USD 0.7294 |
| 13 Mar 2026 | USD 0.7294 |
| 15 Dec 2025 | USD 0.7027 |
| 15 Sep 2025 | USD 0.7027 |
| 13 Jun 2025 | USD 0.7027 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.